Navigation Links
AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease
Date:7/16/2009

LONDON, July 16 /PRNewswire-FirstCall/ -- AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, today announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease.

Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.

The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies.

Alzheimer's disease is a degenerative brain disease for which there is currently no definitive diagnostic tool. Doctors rely on their clinical judgment to diagnose the disease once it has become symptomatic, but the pathologic process very likely starts a few years beforehand.

Professor Paul Maruff, from the Mental Health Research Institute says, "When assessing cognitive function in an individual at risk for dementia on the first occasion, it is often difficult to determine whether their performance on cognitive tests has declined from some previously higher level. The repeated application of a set of brief and simple cognitive measures could therefore help to identify accurately the point when the onset of Alzheimer's disease was imminent in individual people. This could ultimately lead to a more personalized approach with more effective treatments being given to the right patients at the right time."

Dr Judith Jaeger, Director of Neuroscience Early Clinical Development at AstraZeneca adds, "We recognize that in addition to searching for new medicines, we urgently need to find new ways to identify those at risk of developing Alzheimer's disease before they begin to experience symptoms. In addition to developing a novel approach to diagnosing cognitive decline, we hope that our collaboration with the world-class researchers at The Mental Health Research Institute will provide insights that aid our search for new treatments and ways to prevent disease progression."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com/

About AIBL

The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies. The study, consisting of a patient cohort of 1112 participants, will help researchers develop and confirm a set of diagnostic markers biomarkers and psychometrics that can be used to objectively monitor disease progression and to develop hypotheses about diet and lifestyle factors that might delay the onset of this disease. For more information, please visit: www.aibl.csiro.au

About MHRI

The Mental Health Research Institute (MHRI) located in Melbourne is Australia's premiere psychiatric research centre and is working to understand, detect, treat, and prevent mental illnesses. The Institute is formally affiliated with the University of Melbourne and Monash University.


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
3. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
4. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
5. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
6. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
7. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
8. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
9. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
10. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
11. AstraZenecas David Brennan Elected PhRMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, today announced that ... role Dr. Dobke will provide physician oversight for in-house clinical studies and hands-on device ... Surgery and Associate Professor of Surgery at UC San Diego Health and is a ...
(Date:1/24/2017)... IA (PRWEB) , ... January 24, 2017 , ... The ... country, has taken great care to design a program that provides teachers with the ... and domestically. This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate and ... Climate Change and Your Health on Voice America, once again welcomed one of ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... a leading natural supplement for relieving premenstrual syndrome, or PMS . , ... some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is ... by Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... LYNBROOK, N.Y. , Jan. 24, 2017 ... BSTC ), a biopharmaceutical company that originated ... a first in class collagenase-based product collagenase ... ®  in the U.S. and Xiapex ® ... will present a corporate overview at the ...
(Date:1/24/2017)... JOLLA, Calif. , Jan. 24, 2017 ... new case studies using its Biomedical Intelligence® Cloud - ... knowledge from a multitude of genomic, molecular and clinical ... updates were presented at a session hosted by Data4Cure ... Mountain View, CA. The ...
(Date:1/24/2017)... Jan. 24, 2017 Trifecta Clinical , ... is appointing Rick Ward to Vice President ... Trifecta is also announcing the promotion of Ericka ... Rick joins Trifecta from Greenphire where ... held senior business development positions within the healthcare industry ...
Breaking Medicine Technology: